ERCC2 and urinary bladder cancer: For example, a recent microscopy-based nucleotide excision repair assay to profile ERCC2 mutations established a role for ERCC2 helicase domain mutations as a predictive biomarker in bladder cancer treated with cisplatin-based chemotherapy.